The Insulin-Sensitizer Pioglitazone Remodels Adipose Tissue Phospholipids in Humans

The insulin-sensitizer pioglitazone exerts its cardiometabolic benefits in type 2 diabetes (T2D) through a redistribution of body fat, from ectopic and visceral areas to subcutaneous adipose depots. Whereas excessive weight gain and lipid storage in obesity promotes insulin resistance and chronic in...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Juan P. Palavicini, Alberto Chavez-Velazquez, Marcel Fourcaudot, Devjit Tripathy, Meixia Pan, Luke Norton, Ralph A. DeFronzo, Christopher E. Shannon
Formato: article
Lenguaje:EN
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://doaj.org/article/335d5896954c4b0ea9323a843dc2c1dd
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares